site stats

Spro earnings date

WebFind Spero Therapeutics Inc (SPRO) earnings date, revenues, updates and financial reports. Web6 Apr 2024 · April 5, 2024, 9:59 PM · 13 min read. Spero Therapeutics, Inc. (NASDAQ: SPRO) Q4 2024 Earnings Call Transcript March 30, 2024. Operator: Good afternoon, and welcome to Spero Therapeutics Fourth ...

Spero Therapeutics (SPRO) Stock Forecast & Price Target

WebRock paper scissors (also known by other orderings of the three items, with "rock" sometimes being called "stone," or as Rochambeau, roshambo, or ro-sham-bo) is an intransitive hand game, usually played between two people, in which each player simultaneously forms one of three shapes with an outstretched hand.These shapes are … Web15 hours ago · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. SPRO, a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today … fleming\u0027s hours of operation https://reospecialistgroup.com

Spero Therapeutics, Inc. (SPRO) 8-K Earnings Release - Mar 2024

Web10 Apr 2024 · TRKA IPO’d in 2024 at a price of $4.15 and closed yesterday at $0.2990. The $0.3080 area was resistance yesterday and in the pre-market, so should be an important pivot point today. Above it the first target would be yesterday’s high of $0.33. Above the targets are $0.4250, $0.4990, a gap to fill at $0.5600 and then $0.80 and $1 beyond that. Web6 Apr 2024 · Key Earnings Data Earnings ESP 0.00% Most Accurate Est -0.26 Current Qtr Est -0.26 Current Yr Est -1.13 Exp Earnings Date 5/15/23 Prior Year EPS -1.23 Exp EPS Growth (3-5yr) NA Forward PE... WebEarnings Date 05/15/23 Sector Healthcare Industry Biotechnology Avg. Analyst Rec. Premium Beta 2.204 PEG Ratio — Spero Therapeutics Inc. (SPRO) Company Description Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. chegg q a expert login

Q1 2024 EPS Estimates for Fastenal (NASDAQ:FAST) Boosted by …

Category:Research Analysts Offer Predictions for WESCO International, …

Tags:Spro earnings date

Spro earnings date

What date does Spero Therapeutics

Web14 Apr 2024 · Papa John’s International, Inc. (NASDAQ:PZZA – Get Rating) – Analysts at KeyCorp dropped their Q1 2024 earnings per share estimates for Papa John’s International in a report issued on Monday, April 10th.KeyCorp analyst E. Gonzalez now forecasts that the company will post earnings of $0.67 per share for the quarter, down from their previous … Web5 Apr 2024 · Spero Therapeutics (SPRO) to Release Quarterly Earnings on Thursday Spero Therapeutics Reschedules Fourth Quarter and Full Year 2024 Earnings Release and …

Spro earnings date

Did you know?

Web13 Apr 2024 · When is Spruce Power's earnings date? Spruce Power has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, … Web13 Apr 2024 · During the last day, the stock moved $0.120 between high and low, or 7.89%. For the last week, the stock has had daily average volatility of 5.97% . Our recommended stop-loss: $1.56 (-3.66%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 9 days ago.)

Web12 Apr 2024 · The ex-dividend date of this dividend is Tuesday, April 11th. ... Spero Therapeutics, Inc. (NASDAQ:SPRO) Expected to Earn Q1 2024 Earnings of ($0.37) Per Share ... Alcoa (AA) to Release Quarterly ... WebEarnings Peers: Spero Therapeutics (SPRO) is categorized under the Healthcare sector; to help you further research next earnings dates across stocks, below are some other …

http://nextearningsdate.com/spro.html WebS.no Activity T.CODE 1 Define Company OX15 2 Define Company Code OX02 3 Assign Company Code to Company OX16 4 Define Business Area OX03 5 Define Chart of Account OB13 6 Assing Company Code to Chart of Accounts OB62 7 Define Account Group OBD4 8 Define Retained Earnings Account OB53 9 Maintain Fiscal Year Varient OB29 10 Assign …

Web30 Mar 2024 · Spero Therapeutics, Inc. (SPRO) SEC Filing 8-K Material Event for the period ending Thursday, March 30, 2024. Home. SEC Filings. Spero Therapeutics, Inc. (SPRO) 8-K Material Event Thu Mar 30 2024; SEC Filings. SPRO Valuations. Intrinsic Value. ... Earnings Release Financial Exhibit.

Web8 Apr 2024 · SPRO Earnings Date and Information. Spero Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 15th, 2024 based off prior year's report dates. fleming\u0027s hotel schwabingWeb31 Mar 2024 · Spero Therapeutics, Inc. (SPRO) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of a loss of $0.40 per share. This compares to loss of $0.90 per share... fleming\u0027s houston menuWebSpero Therapeutics (SPRO) Earnings Date & Reports 409 Followers Portfolio Earnings Data Report Date Apr 03, 2024 Not Confirmed Period Ending 2024 (Q4) Consensus EPS Forecast -$0.35 Last Year’s EPS -$1.01 Same Quarter Last Year Analyst Consensus Moderate Buy Based on 1 Analysts Ratings Spero Therapeutics (SPRO) Earnings, Revenues Date & History chegg raise a ticketWeb30 Mar 2024 · On this page, you can find detailed information about the financial performance of Spero Therapeutics Inc, including the latest Spero Therapeutics Inc … fleming\u0027s houston texasWeb12 Apr 2024 · The technology company reported $4.13 earnings per share for the quarter, beating the consensus estimate of $3.81 by $0.32. The company had revenue of $5.60 billion during the quarter, compared to ... chegg quarterly earning report dateWeb15 hours ago · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and ... chegg ratings reviewsWeb1 day ago · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced two … chegg read ebook offline